Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Hopkins scientists design new mouse that mimics common form of leukemia

Hopkins scientists design new mouse that mimics common form of leukemia

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

New drug combination therapy effectively kills cancer cells

New drug combination therapy effectively kills cancer cells

Discoveries pave way for use of new therapies for advanced thyroid cancer

Discoveries pave way for use of new therapies for advanced thyroid cancer

Antioxidant substances in red wine, dark chocolate, olive oil linked with health benefits

Antioxidant substances in red wine, dark chocolate, olive oil linked with health benefits

FDA grants Priority Review designation to sNDA for Nexavar tablets

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Study provides important details for recently identified target in lung adenocarcinoma

Study provides important details for recently identified target in lung adenocarcinoma

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Researchers evaluate Pexa-Vec to slow progression of liver cancer

Researchers evaluate Pexa-Vec to slow progression of liver cancer

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

FDA's Oncologic Drugs Advisory Committee to review NDA for tivozanib

FDA's Oncologic Drugs Advisory Committee to review NDA for tivozanib

Tivozanib overall survival results announced by AVEO and Astellas

Tivozanib overall survival results announced by AVEO and Astellas

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.